Continuous subcutaneous apomorphine monotherapy in Parkinson’s disease

Introduction and objective Continuous subcutaneous apomorphine (APO) treatment is one of the 3 therapeutic options for advanced Parkinson’s disease (PD), in addition to deep brain stimulation (DBS) and intrajejunal levodopa. Data from previously performed studies show that few PD patients can achiev...

Full description

Bibliographic Details
Main Authors: Ewa Papuć, Olga Trzciniecka, Konrad Rejdak
Format: Article
Language:English
Published: Institute of Rural Health 2019-03-01
Series:Annals of Agricultural and Environmental Medicine
Subjects:
Online Access:http://www.journalssystem.com/aaem/Continuous-subcutaneous-apomorphine-monotherapy-in-Parkinson-s-disease,99699,0,2.html